Tandem Diabetes (TNDM) Tops Q2 EPS by 5c

Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $23 million versus the consensus estimate of $23.08 million.

GUIDANCE:

Tandem Diabetes sees FY2016 revenue of $105-110 million, versus the consensus of $111.13 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance